In vitro and in vivo kinetic interactions of the antitumour agent 5,6-dimethylxanthenone-4-acetic acid with thalidomide and diclofenac

Cancer Chemotherapy and Pharmacology

Volumn 47, Issue 4, 2001, Pages 319-326

  Zhou, Shufeng ^a   Paxton, James W ^a   Kestell, Philip ^b   Tingle, Malcolm D ^a   Ching, Lai Ming ^b  

^a UNIVERSITY OF AUCKLAND   (New Zealand)

^b UNIVERSITY OF AUCKLAND   (New Zealand)

Author keywords

DMXAA; Drug interaction; Glucuronidation; L Thalidomide

Indexed keywords

2,5 DIMETHYLXANTHENONE 4 ACETIC ACID; 5,6 DIMETHYLXANTHENONE 4 ACETIC ACID; ANTINEOPLASTIC AGENT; DICLOFENAC; PLASMA PROTEIN; SN 24350; THALIDOMIDE; UNCLASSIFIED DRUG; XANTHENE DERIVATIVE; 5,6 DIMETHYLXANTHENONEACETIC ACID; 5,6-DIMETHYLXANTHENONEACETIC ACID; NONSTEROID ANTIINFLAMMATORY AGENT; TERATOGENIC AGENT; XANTHONE DERIVATIVE;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; AREA UNDER THE CURVE; ARTICLE; COMPETITIVE INHIBITION; CONTROLLED STUDY; DRUG GLUCURONIDATION; DRUG HALF LIFE; DRUG HYDROXYLATION; DRUG METABOLISM; DRUG PROTEIN BINDING; FEMALE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN TISSUE; IN VITRO STUDY; IN VIVO STUDY; LIVER MICROSOME; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; ULTRAFILTRATION; ANIMAL; C57BL MOUSE; DRUG EFFECT; DRUG INTERACTION; METABOLISM; PROTEIN BINDING;

ANIMALS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ANTINEOPLASTIC AGENTS; BLOOD PROTEINS; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; DICLOFENAC; DRUG INTERACTIONS; FEMALE; HUMANS; MALE; MICE; MICE, INBRED C57BL; MICROSOMES, LIVER; PROTEIN BINDING; TERATOGENS; THALIDOMIDE; XANTHENES; XANTHONES;

EID: 0034743321     PISSN: 03445704     EISSN: None     Source Type: Journal    
DOI: 10.1007/s002800000249     Document Type: Article

References (37)

1. Thalidomide increases both intra-tumoural tumour necrosis factor-α production and antitumour activity in response to 5,6-dimethylxanthenone-4-acetic acid
2. Preparation of one optical antipode of 2-phthalimidoglutarimide
3. In vitro protein binding of diclofenac sodium in plasma and synovial fluid
4. Plasma pharmacokinetics and urinary excretion of thalidomide after oral dosing in healthy male volunteers
5. Effect of thalidomide on tumour necrosis factor production and antitumour activity induced by 5,6-dimethylxanthenone-4-acetic acid
6. Interaction of thalidomide, phthalimide analogues of thalidomide and pentoxifylline with the antitumour agent 5,6-dimethylxanthenone-4-acetic acid: Concomitant reduction of serum tumour necrosis factor-alpha and enhancement of antitumour activity
7. Induction of intratumoral tumor necrosis factor (TNF) synthesis and hemorrhagic necrosis by 5,6-dimethylxanthenone-4-acetic acid (DMXAA) in TNF knockout mice
8. Clinical pharmacokinetics of diclofenac: Therapeutic insights and pitfalls
9. Tissue binding versus plasma binding of drugs: General principles and pharmacokinetic consequences
10. Systematic screening for pharmacokinetic interactions during drug development
11. Prediction of pharmacokinetic alterations caused by drug-drug interactions: Metabolic interaction in the liver
12. Phase I pharmacokinetic and pharmacodynamic study of 5,6-dimethylxanthenone-4-acetic acid (DMXAA), a novel antivascular agent
13. The pharmacokinetics and metabolism of diclofenac sodium (Voltarol) in animals and man
14. Urinary excretion of 5,6-dimethylxanthenone-4-acetic acid (DMXAA) and its metabolites in cancer patients undergoing a phase I clinical trial
15. Plasma disposition, metabolism and excretion of the experimental antitumour agent 5,6-dimethylxanthenone-4acetic acid in the mouse, rat and rabbit
16. Modulation of the plasma pharmacokinetics of 5,6-dimethylxanthenone-4-acetic acid by thalidomide in mice
17. Thalidomide and derivatives - Immunological investigations of tumour necrosis factor-alpha (TNF-alpha) inhibition suggest drugs capable of selective gene regulation
18. Preclinical prediction of factors influencing the elimination of 5,6-dimethylxanthenone-4-acetic acid, a new anticancer drug
19. Suppression of cytochrome P450- and UDP glucuronosyltransferase-dependent enzyme activities by proinflammatory cytokines and possible role of nitric oxide in primary cultures of pig hepatocytes
20. 14C-labelled thalidomide in pregnant mice
21. The carbon monoxide binding pigment of liver microsomes. I. Evidence for its hemoprotein nature
22. Antitumour activity of the novel immune modulator 5,6-dimethylxanthenone-4-acetic acid (DMXAA) in mice lacking the interferon-gamma receptor
23. Induction of tumour necrosis factor-alpha by single and repeated doses of the antitumour agent 5,6-dimethylxanthenone-4-acetic acid
24. Light-induced breakdown of flavone acetic acid and xanthenone analogues in solution
25. Potential antitumour agents. 61. Structure-activity relationships for in vivo colon 38 activity among disubstituted 9-oxo-9H-xanthenone-4-acetic acids
26. Characterisation of theophylline metabolism by human liver microsomes
27. Disposition of thalidomide in rabbits and rats
28. Measurement of protein using bicinchoninic acid
29. Hepatic cytochrome P450 is directly inactivated by nitric oxide, not by inflammatory cytokines, in the early phase of endotoxemia
30. Evidence for the production of nitric oxide by activated macrophages treated with the antitumor agents flavone-8-acetic acid and xanthenone-4-acetic acid
31. Tumor-dependent increased plasma nitrate concentrations as an indication of the antitumor effect of flavone-8-acetic acid and analogues in mice
32. Binding of thalidomide to alpha(1)-acid glycoprotein may be involved in its inhibition of tumor necrosis factor alpha production
33. Metabolism and elimination of 5,6-dimethylxanthenone-4-acetic acid in the isolated perfused rat liver
34. Pharmacokinetic studies on diclofenac sodium in young and old volunteers
35. Determination of two major metabolites of the novel antitumour agent 5,6-dimethylxanthenone-4-acetic acid in hepatic microsomal incubations by high- performance liquid chromatography with fluorescence detection
36. Identification of the human liver cytochrome P450 isozyme responsible for the 6-methyl hydroxylation of the novel anticancer drug 5,6-dimethylxanthenone-4-acetic acid
37. Reversible binding of the novel antitumour agent 5,6-dimethylxanthenone-4-acetic acid to plasma proteins and blood cells in various species